Sisram Medical Completes Inaugural Pilot of Alma's European Medical Faculty

Advancing Clinical Research and R&D Integration to Solidify Long-Term EDB Competitiveness

HONG KONG, November 18, 2026-- Sisram Medical Ltd (the **"Company"** or **"Sisram"**, 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today announced that the successful conclusion of the inaugural European Medical Faculty Meeting hosted by its EBD brand, Alma, at Alma Care in Rome, Italy, from November 6 to 8. The event brought together approximately 15 experienced physicians from Europe and the Middle East for in-depth exchanges on core technology platforms, future product pipelines, clinical applications, and joint research initiatives. Its successful completion marks a key milestone in the pilot phase of Alma's Medical Faculty initiative, paving the way for its broader implementation.

Designed to foster sustained, structured partnerships with leading medical experts, the European Medical Faculty moves beyond conventional product training and one-way engagement with key opinion leaders (KOLs) toward a more integrated model of scientific exchange and clinical innovation. Centered on flagship platforms including Alma Hybrid and Alma Harmony, participating physicians shared practical insights into technology applications, treatment protocols, and emerging clinical needs, offering valuable perspectives on both established products and technologies under development. The discussions also helped identify shared research priorities and potential joint projects, laying the foundation for future clinical studies, real-world evidence generation, and scientific publications.

By embedding clinical expertise more deeply into its innovation process, Alma aims to establish a closer connection between frontline medical practice, scientific research, and product development. For its established portfolio, ongoing scientific engagement is expected to enrich the clinical evidence base, explore broader treatment applications, and further differentiate the value proposition of its technologies. For next-generation platforms, early involvement of experienced practitioners will help inform product design and technical validation, ensuring closer alignment with evolving clinical needs and facilitating the translation of innovation into practical applications. At the same time, sustained engagement with leading physicians will provide a strong foundation for pre-launch medical education, professional adoption, and subsequent market development. Together, these initiatives are expected to enhance R&D responsiveness, accelerate product evolution, and fortify Alma's competitive position in the global EBD market through evidence-driven innovation.

Building on the Rome pilot, Sisram plans to progressively expand the Medical Faculty model across its key international markets, establishing a Global Medical Faculty supported by Regional Medical Faculties in Europe, North America, Latin America (LATAM), China, and Japan and Asia-Pacific (JPAC). The Global Medical Faculty will convene internationally recognized physicians as long-term scientific partners to explore emerging technologies, shape research priorities, and assess evolving clinical trends. Complementing this global perspective, the Regional Medical Faculties will focus on market-specific clinical requirements, facilitate collaborative studies and professional education, and nurture the next generation of medical leaders. Through this coordinated global and regional framework, Sisram aims to create a more cohesive medical and scientific network that supports

continuous product innovation, enhances clinical capabilities, and facilitates the introduction of future technologies across international markets.

“The EBD business remains the cornerstone of Sisram’s global operations, and our long-term competitiveness is built on continuous innovation underpinned by proven clinical value,” said **Mr. Eyal Ben David, CEO of Sisram.** “The successful pilot of Alma’s European Medical Faculty represents an important step in establishing a more systematic framework for scientific collaboration, bringing clinical expertise closer to the heart of our innovation process. By connecting leading medical professionals with our global R&D capabilities, we aim to accelerate technology validation, advance product development, and unlock new clinical applications. Looking ahead, we will continue to deepen global medical partnerships, harness clinical insights to drive meaningful innovation, and further strengthen Alma’s competitive position in the global EBD market. Through these efforts, we are committed to delivering sustainable, high-quality growth and creating lasting value for our customers and shareholders.”

About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company’s synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.

For more information, please visit: www.sisram-medical.com.

For Investor Relations inquiries, please contact:
IR@sisram-medical.com